The article provides an overview of the latest analyst ratings for Regenxbio. Five analysts have published their opinions on the stock, with an average 12-month price target of $41.2. This represents a 7.93% decrease from the previous average price target of $44.75. The ratings are a mix of bullish, somewhat bullish, and indifferent, with no bearish ratings. Given the mixed opinions and the decrease in the average price target, the short-term impact on the stock price is likely to be neutral.